Our findings are concordant with clinical/laboratory data that demonstrated a suppression in angiogenesis due to an increase in angiogenic inhibitors in patients with diabetes combined with an increase in CXCL10 and TIMP1 expression at the transcriptional and protein levels [44, 45]. The gene discussed is TIMP1; the disease is diabetes mellitus.